Avanos Medical, Inc.
AVNS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.08 | 0.03 | -2.16 |
| FCF Yield | 11.32% | 1.40% | 5.64% | 3.98% |
| EV / EBITDA | -2.30 | 23.06 | 18.23 | 35.51 |
| Quality | ||||
| ROIC | 3.80% | 5.51% | 1.94% | 5.05% |
| Gross Margin | 55.44% | 56.39% | 57.62% | 51.02% |
| Cash Conversion Ratio | -0.26 | -0.52 | 1.80 | 16.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.18% | -3.30% | -1.45% | 2.20% |
| Free Cash Flow Growth | 467.81% | -79.61% | 7.99% | 392.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.18 | 2.40 | 1.92 | 1.41 |
| Interest Coverage | 3.28 | 4.33 | 4.19 | 26.30 |
| Efficiency | ||||
| Inventory Turnover | 2.21 | 1.80 | 1.52 | 2.43 |
| Cash Conversion Cycle | 171.10 | 210.31 | 243.69 | 158.29 |